B+
Bull case
20%
Probability
Target price
$8.20
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
HBIO
Harvard BioscienceDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
55%
Probability
Target price
$7.20
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$4.80
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-14
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+45.2
Score
AI commentary
The earnings release tone is mildly constructive, but the evidence is primarily company-reported operating data. Q2 revenue growth and the raised full-year outlook are positive; margin mix, losses, negative operating cash flow, and capital-structure risk temper the signal. A reliable post-release price-reaction series and analyst target revisions are unavailable, while social coverage is absent, so this remains a cautious monitoring view.
RankAlpha Sentiment Codex - 2026-08-14
Open post-earnings memoEvidence flagged
Coverage is limited for this name, so the memo relies on a thinner evidence base.; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-08-11eventQ2 growth and raised full-year revenue outlookHigh impact
Q2 revenue rose 11% year over year to $22.7 million, adjusted EBITDA increased to $1.7 million, and management raised full-year 2026 revenue-growth guidance to 3%-5%. The company cited demand across CMT, AAA, electroporation, China, and its NPI pipeline. [#SEC-8K-2026-08-11]
2026-11-12eventQ3 execution against explicit operating rangesMedium impact
The company guided Q3 revenue to $21.0-$22.6 million, adjusted gross margin to 56%-58%, and adjusted EBITDA to $1.5-$2.5 million. Delivery would support the improved demand narrative; a miss would challenge the recent guidance raise. [#SEC-8K-2026-08-11]
2026-12-31catalystBalance-sheet de-risking and covenant durabilityHigh impact
The balance-sheet repair thesis requires sustained proof across 2026: the prior baseline reported $7.1 million of cash against $40 million of borrowings, with minimum-liquidity and adjusted-EBITDA covenants plus warrant overhang. Sustained covenant compliance, positive cash conversion, or another financing action would reduce capital-structure risk. [#10-Q-2026-05-12][#10-K-2026-03-13]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-14 • Updated nightlySource: Internal modelMethodology